Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Renin-Angiotensin system inhibitors and blood pressure control
7 evidence topics · 6 sources
Renin-angiotensin system inhibitor recommendations: KDIGO 2024 CKD guideline
Supportive treatment for FSGS: KDIGO 2021 glomerular diseases guideline
Blood pressure control after a high-risk APOL1 genotype is confirmed: Delphi consensus
“After a patient with CKD is confirmed to have a high-risk APOL1 genotype, the clinician should:” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Inform the patient about other modifiable risk factors and renoprotective measures (lifestyle changes, BP control)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blood pressure goal and ACE inhibitor effects by APOL1 genotype in AASK
“In the AASK study, the primary outcome occurred in 58.1% of the patients in the APOL1 high-risk group and in 36.6% of those in the APOL1 low-risk group (hazard ratio in the high-risk group, 1.88; P<0.001). There was no interaction between APOL1 status and trial interventions or the presence of baseline proteinuria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“there was no significant interaction between APOL1 status and the randomized blood-pressure goal with respect to the progression of chronic kidney disease (P = 0.72 for interaction)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The lack of significant interaction between APOL1 and treatment with an ACE inhibitor suggests that patients in the APOL1 high-risk group still benefit from this class of drugs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Strict blood pressure control and mortality by APOL1 genotype in AASK
“This included 682 participants with known APOL1 genotype (157 with high-risk genotype) previously assigned to either strict (mean arterial pressure [MAP] 92 mm Hg or less) versus usual blood pressure control (MAP 102-107 mm Hg) during the trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the APOL1 high-risk group, risk of death was 42% lower comparing strict versus usual blood pressure control (0.58 [0.35-0.97]). In the APOL1 low-risk group, risk of death comparing strict versus usual blood pressure control was not significantly different (1.09 [0.84-1.43]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote